Tesamorelin

Fatty Liver Disease

Hudson Biotechprotein_peptidePhase 2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 89/ 100

Competitive context

26 Active assets in the Fatty Liver Disease cohort.

Asset / Sponsor	Phase	Rating
Metformin Leiden University Medical Center	Phase 4	BBB
Alpha Tocopherol Yuen Kah Hay	Phase 4	BB
Raltegravir Helsinki University Central Hospital	Phase 4	BB
Pioglitazone Seoul National University Bundang Hospital	Phase 4	BB
Dolutegravir Fundacion SEIMC-GESIDA	Phase 4	BB

View all 50 →

Same molecule, other indications

Tesamorelin is also rated in:

lipodystrophyDormant

B

Indicative · Phase 3

62 / 100

isolated congenital growth hormone deficiencyDormant

B

Indicative · Phase 4

60 / 100

HIV infectious diseaseDormant

B

Indicative · Phase 3

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.